Canopy Growth (HAM:11L) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:11L Canopy Growth Corp HAM:11L
60 GF Score
Price €0.78
GF Value €0.65
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Canopy Growth Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

HAM:11L
60GF Score
Canopy Growth Corp HAM:11L
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Canopy Growth (HAM:11L) Overvalued in 2026?

Based on GuruFocus' analysis, Canopy Growth stock appears to be overvalued. The current stock price of €0.78 is trading 20% above its estimated GF Value™ of €0.65. GuruFocus considers Canopy Growth to be Modestly Overvalued.

Key valuation signals for HAM:11L:

  • Dividends Received:
  • GF Value™: €0.65 vs. price of €0.78 (20% above fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the HAM:11L stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Canopy Growth Business Description

Address 1 Hershey Drive, Smiths Falls, ON, CAN, K7A 0A8
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.
60GF Score

Get the complete analysis for HAM:11L

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.78
Price
€0.65
GF Value